Ceftobiprole News
Most Popular Ceftobiprole Story
ALSO NOTED: GSK faces Tyverb setback over safety; Boehringer warns of inhaler's stroke risk;
> GlaxoSmithKline's cancer med Tyverb--sold in the U.S. as Tykerb--faces a reassessment for European approval on news that a small number of patients have suffered liver side effects. Release >... Read more...
Latest Headlines
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
